Vertex Pharmaceuticals Incorporated : 2025 Data Summary
VRTX
Published on 04/16/2026 at 12:00 pm EDT
We monitor and report metrics in areas that align with our corporate responsibility priorities. The table below discloses our three-year progress on select indicators.
METRIC
2025
2024
2023
BUSINESS AND ETHICS
R&D Investment (GAAP, in USD thousands)
4,042,500
8,258,7001
3,690,000
R&D Investment as a Percentage of Business Operating Expenses (GAAP)
70%
85%
77%
% of Employees Who Completed Their Annual Code of Conduct Training
100%
100%
100%
% Spend on Small Businesses2
13.8%
17.3%
18.1%
WORKPLACE
Total Employees Globally (approximate)
6,400
6,100
5,100
New Hires Globally (approximate)
900
1,100
1,100
Voluntary Turnover Rate (Global, Trailing 12 Months Metric)
5.6%
4.4%
4.7%
COMMUNITY
Nonprofits Supported Through Matching Gift Program
2,775
2,592
2,183
Hours Volunteered by Employees During Work Time
13,974
12,715
10,013
% of Employees Who Volunteered on Global Week of Service
83%
70%
60%
ENVIRONMENT, HEALTH, SAFETY AND SUSTAINABILITY
TRIR (per 200,000 hours worked)3
0.13
0.18
0.33
DART (per 200,000 hours worked)3
0.12
0.16
0.15
% Square Feet of Buildings Operated That Are Green Certified
80%
79%4
82%4
2024 R&D Investment included a one-time acquired in-process research and development expense of $4.4 billion resulting from our acquisition of Alpine Immune Sciences, Inc.
For the 2025 U.S. gov. fiscal year (Oct. 1, 2024-Sep. 30, 2025).
ERM CVS provided limited assurance of safety rates (TRIR, DART) for 2020-2025. Assurance information for 2020-2024 can be found in the associated corporate responsibility (CR) reports. The 2025 ERM CVS Assurance Report and Basis of Reporting can be viewed at https://www.vrtx.com/responsibility/policies-positions-and-reports.
Percentage decreased due to an increase in our global footprint.
Vertex 2025 Data Summary | 1
METRIC
2025
2024
2023
Total GHG Emissions Scope 1 & Scope 2 Market-Based (metric tons CO2e)5,6
13,574
12,906
13,198
GHG Scope 1 (metric tons CO2e)5
12,296
8,976
8,311
GHG Scope 2 (metric tons CO2e)5,6
1,278
3,930
4,888
GHG Scope 3 (metric tons CO2e)
579,649
551,647
474,129
CDP Climate Change Survey Score
B
B
A-
% Energy From Renewable Sources
52%
50%
49%
Total Waste (metric tons)7
2,109
1,982
1,689
Nonhazardous Waste (metric tons)5,7
1,444
1,467
1,212
Nonhazardous Waste Diverted From Landfill (metric tons)5,7
588.8
596.7
403.1
% Nonhazardous Waste Recycled or Composted5,7
41%
41%
33%
Hazardous Waste (metric tons)5,7
664.5
514.7
476.9
Laboratory and Manufacturing Waste Recycled (metric tons)5
174.3
130.0
119.6
% Total Waste Diverted From Landfill5,7,8
59%
57%
52%
Total Water Withdrawn (megaliters)
188.4
137.8
169.3
2022 and 2023 GHG Scope 1 emissions were updated in April 2025 to include emissions at our Vertex Manufacturing Center that were previously attributed to a tenant. ERM CVS provided limited assurance of total GHG Emissions Scope 1 & Scope 2 Location- and Market-Based (metric tons CO2e), and waste data for 2020-2025. ERM CVS provided limited assurance of total GHG Emissions Scope 1 & Scope 2 Location- and Market-Based (metric tons CO2e), and waste data for 2020-2025. ERM CVS also provided reasonable assurance of Fan Pier Scope 1 (4,939 MT C02e), Scope 2 Location-Based (7,131 MT CO2e), and Scope 2 Market-Based (70.7 MTCO2e); UK IHQ Scope 1 (1.29 MT C02e), Scope 2 Location-Based (131 MT CO2e), and Scope 2 Market-Based (0 MTCO2e) for 2025. Assurance information for 2020-2024 can be found in the associated corporate responsibility (CR) reports. The 2025 ERM CVS Assurance Report and Basis of Reporting can be viewed at https://www.vrtx.com/sites/default/files/Environmental-Assurance-Statements.pdf.
Location-based Scope 2 emissions were 15,443 MT CO2e. For Scope 2 market-based emissions, international locations apply location-based IEA factors when residual emission factors set are not available.
8 Includes hazardous and nonhazardous waste diverted from landfill via recycling, composting, fuel blending and incineration for repurposing or energy recovery.
Waste figures represent waste associated with Vertex operations. This includes small-scale internal renovations but excludes expansions and new building construction.
Vertex 2025 Data Summary | 2
Vertex 2025 Data Summary |
Disclaimer
Vertex Pharmaceuticals Incorporated published this content on April 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 16, 2026 at 15:59 UTC.